Editas Medicine: CRISPR technology with great potential

• Editas Medicine has entered into a license agreement with Vertex Pharmaceuticals for the development of CRISPR/Cas9-based therapies for Duchenne muscular dystrophy.
• Editas Medicine has a strong pipeline portfolio with several promising candidates in clinical development.
• Conclusion: Editas Medicine is a good buy for investors interested in the future of CRISPR technology.